Oncology (all articles)
#ASCO22 – Phase 2 single-arm study: Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation.
6 Jun, 2022 | 11:15h | UTCAdagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Targeted drug achieves 43% response rate in KRAS-mutated lung cancer – Dana-Farber Cancer Institute
#ASCO22 – Phase 2 single-arm study: PD-1 Blockade in mismatch repair–deficient, locally advanced rectal cancer.
6 Jun, 2022 | 11:12h | UTCPD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
#ASCO22 – Phase II RCT: Ramucirumab and pembrolizumab vs. standard of care in advanced non–small-cell lung cancer previously treated with immunotherapy.
6 Jun, 2022 | 11:14h | UTCCommentary: New drug combination lengthened survival for some with lung cancer – SWOG Cancer Research Network
Commentary on Twitter
https://twitter.com/JCO_ASCO/status/1532785457947414531
#ASCO22 – RCT: Triplet therapy, transplantation, and maintenance until progression in myeloma.
6 Jun, 2022 | 11:06h | UTCTriplet Therapy, Transplantation, and Maintenance until Progression in Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
DETERMINATION: Among adults with multiple myeloma, continuous lenalidomide maintenance therapy after triplet therapy (RVD, plus ASCT) associated with longer PFS than triplet therapy alone. #ASCO22 https://t.co/YhKgjc1Enz pic.twitter.com/cU8nefokZo
— NEJM (@NEJM) June 5, 2022
#ASCO22 – Phase 1-2 single-arm study: Teclistamab in relapsed or refractory multiple myeloma.
6 Jun, 2022 | 11:11h | UTCTeclistamab in Relapsed or Refractory Multiple Myeloma – New England Journal of Medicine
Commentary on Twitter
MajesTEC-1: Teclistamab resulted in a high incidence of deep and durable response in patients with triple-class–exposed relapsed or refractory multiple myeloma. #ASCO22 https://t.co/Nanjob1q7p pic.twitter.com/oqfaiu8MOx
— NEJM (@NEJM) June 5, 2022
Guidance paper for carcinoid syndrome and carcinoid heart disease.
3 Jun, 2022 | 11:26h | UTC
Consensus Statement: Current role of immunotherapy in gastric, esophageal and gastro-esophageal junction cancers.
3 Jun, 2022 | 11:24h | UTC
Prospective comparison of medical oncologists vs. a machine learning model to predict 3-month mortality in patients with metastatic solid tumors.
3 Jun, 2022 | 11:22h | UTC
Commentary on Twitter
When the machines outperformed 74 oncologists for predicting outcomes in a prospective study of over 2,000 patients with advanced cancer #AIhttps://t.co/UmfjRhZak2 @JAMANetworkOpen pic.twitter.com/5zJSb0qv0g
— Eric Topol (@EricTopol) May 31, 2022
Nationwide cohort study: Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer.
3 Jun, 2022 | 11:10h | UTCCommentary: ADT for Prostate Cancer: What’s the Risk on the Heart? – Medscape (free registration required)
Summary of best evidence for enhanced recovery after surgery for patients undergoing lung cancer operations.
3 Jun, 2022 | 11:02h | UTCRelated:
Preoperative exercise training for patients with non‐small cell lung cancer – Cochrane Library
Cardiac metastasis from solid cancers: a 35-year single-center autopsy study.
3 Jun, 2022 | 10:54h | UTC
Review: Integration of genomic biology into therapeutic strategies of gastric cancer peritoneal metastasis.
3 Jun, 2022 | 10:51h | UTC
A systematic review of the guidelines on venous thromboembolism prophylaxis in gynecologic oncology.
3 Jun, 2022 | 10:48h | UTC
M-A: Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer.
3 Jun, 2022 | 10:46h | UTC
Clinical practice guidelines for penile cancer.
2 Jun, 2022 | 10:57h | UTC
RCT: Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
2 Jun, 2022 | 10:49h | UTCDurvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer – NEJM Evidence
Commentary on Twitter
Durvalumab, with gemcitabine plus cisplatin, increased median overall survival, 12.8 months versus 11.5 months, in patients with previously untreated unresectable, recurrent or metastatic biliary tract cancer. https://t.co/SaeUxfGfWd#OncTwitter #MedTwitter #Cholangiocarcinoma pic.twitter.com/NZeVljWnyu
— NEJM Evidence (@NEJMEvidence) June 1, 2022
RCT: Effect of reflectance confocal microscopy for suspect lesions on diagnostic accuracy in melanoma.
2 Jun, 2022 | 10:41h | UTC
Commentary on Twitter
In this RCT, adjunctive use of reflectance confocal microscopy for suspicious lesions is proven to reduce unnecessary excisions and removes all aggressive melanomas at baseline in a real-life, prospective clinical decision making setting. https://t.co/cWJu9TlaEH
— JAMA Dermatology (@JAMADerm) June 1, 2022
Phase 2 RCT: Efficacy of epigallocatechin-3-gallate in preventing dermatitis in patients with breast cancer receiving postoperative radiotherapy.
2 Jun, 2022 | 10:34h | UTCEfficacy of Epigallocatechin-3-Gallate in Preventing Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy: A Double-Blind, Placebo-Controlled, Phase 2 Randomized Clinical Trial – JAMA Dermatology (free for a limited period)
Visual Abstract: Efficacy of Epigallocatechin-3-Gallate on Dermatitis in Patients With Breast Cancer Receiving Postoperative Radiotherapy
M-A: Association between benign ovarian tumors and ovarian cancer risk.
2 Jun, 2022 | 10:18h | UTC
Expert Analysis: Cardiotoxicity and the evolving landscape of HER2-targeted breast cancer treatment.
2 Jun, 2022 | 10:11h | UTC
ASCO Guideline Update: Systemic therapy for advanced human epidermal growth factor receptor 2–positive breast cancer.
1 Jun, 2022 | 11:38h | UTC
Commentary on Twitter
Out on JCO the latest @ASCO Guidelines Update on the treatment of HER2-positive ABC. Key points: standard first line remains THP, new second line is T-DXd, no standard after progression to T-DXd, a setting for which we urgently need data.https://t.co/2mMxBLACmf pic.twitter.com/2sXpzqz4ym
— Paolo Tarantino (@PTarantinoMD) June 1, 2022
ASCO Guideline Update: Management of advanced human epidermal growth factor receptor 2–positive breast cancer and brain metastases.
1 Jun, 2022 | 11:36h | UTC
Commentary on Twitter
🚨 Just published in #JCO: Guideline update on management of advanced human epidermal growth factor receptor 2–positive #breastcancer and #brainmetastases.
Read more ➡️ https://t.co/fz0lfJE8zb #bcsm #btsm #brainmets pic.twitter.com/C7tyCsVGR7
— Journal of Clinical Oncology (@JCO_ASCO) May 31, 2022
Retrospective Cohort Study: Colonoscopy surveillance following adenoma removal to reduce the risk of colorectal cancer.
1 Jun, 2022 | 11:17h | UTC
Update on perioperative management of patients undergoing surgery for liver cancer.
1 Jun, 2022 | 11:11h | UTC
Cohort Study: Taking 5-ARIs for BPH is not associated with increased mortality in prostate cancer.
1 Jun, 2022 | 10:59h | UTCNews Release: Taking 5-ARIs for BPH is not associated with increased mortality in prostate cancer – Karolinska Institute
Original Study: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA Oncology (link to abstract – $ for full-text)
Authors Interview: Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality – JAMA
Commentary: Large study finds no increased risk for prostate cancer death with 5-ARI use – medwire News
Commentary on Twitter
This large population-based cohort study found that men treated with 5α-reductase inhibitors had no increased risk of dying from #prostatecancer, on the contrary indicating a decreased risk with longer treatment duration. https://t.co/y8HlpthNI9 #PCSM #GUCSM
— JAMA Oncology (@JAMAOnc) May 19, 2022